Krishnansu S. Tewari, MD of University of California, Irvine explains what CA4P is. CA4P is a vascular disrupting agent (VDA), which is thought to work by blocking the blood supply inside the tumor, depriving it of oxygen and nutrients, which leads to cell death. CA4P is being developed by Mateon Therapeutics in South San Francisco, CA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
What is CA4P?
